Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial (Q41461677)

1 October 2017

Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial (English)

1 reference

1 October 2017

1 reference

Nabil Ben Chaabane

1

1 reference

1 October 2017

Hamad Saadoon Al-Adhba

series ordinal

2

1 reference

1 October 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

Indian Journal of Gastroenterology

1 October 2017

1 reference

1 October 2017

34

1 reference

1 October 2017

1

1 reference

1 October 2017

68-72

1 reference

https://scigraph.springernature.com/pub.10.1007/s12664-015-0535-x

1 October 2017

0 references

cites work

Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: scenario from Saudi Arabia

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Risk factors for cancer development in Helicobacter pylori gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: a randomized comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Factors associated with treatment failure of Helicobacter pylori infection in a developing country

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

High eradication rates of Helicobacter pylori with a new sequential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Epidemiology of Helicobacter pylori Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-015-0535-X

Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China

21 January 2018

1 reference

12 December 2020

Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.

1 reference

12 December 2020

Sequential therapy for Helicobacter pylori eradication: a critical review

1 reference

12 December 2020

Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole

1 reference

12 December 2020

A randomized trial comparing four Helicobacter pylori eradication regimens: standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy

1 reference

12 December 2020

Treatment of Helicobacter pylori infection

1 reference

12 December 2020

10.1007/S12664-015-0535-X

Identifiers

DOI

1 reference

Dimensions Publication ID

1 October 2017

0 references

1 reference